Downgrades Outperform Neutral X

JNCE Jounce Therapeutics

Robert W. Baird

$15 $7

Upgrades Outperform Strong Buy X

JNCE Jounce Therapeutics

Raymond James

$15 $20

Initiated Outperform X

JNCE Jounce Therapeutics

SMBC Nikko

$17

Upgrades Mkt Perform Outperform X

JNCE Jounce Therapeutics

Cowen

Initiated Overweight X

JNCE Jounce Therapeutics

Piper Sandler

$20

Downgrades Neutral Underweight X

JNCE Jounce Therapeutics

JP Morgan

Initiated Outperform X

JNCE Jounce Therapeutics

Raymond James

Downgrades Outperform Mkt Perform X

JNCE Jounce Therapeutics

Wells Fargo

Initiated Buy X

JNCE Jounce Therapeutics

H.C. Wainwright

$33

JNCE  Jounce Therapeutics, Inc.

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates Inducible T cell CO-Stimulator (ICOS) and is in a Phase II trial.